Mounjaro®
The Eli Lilly branded tirzepatide injector — FDA-approved May 13, 2022 for glycemic control in adults with type 2 diabetes. Same active molecule as Zepbound® and compounded tirzepatide. Prescribed online by US-licensed doctors with insurance verification and LillyDirect cash-pay support.
- FDA-approved for type 2 diabetes (May 2022)
- Dual GIP/GLP-1 co-agonist — first-in-class incretin
- A1C reductions up to ~2.4% in SURPASS pivotal trials
- Insurance billing or LillyDirect cash-pay options
shipping
doctors
doctor 24/7
- Same price at every dose. No hidden fees.
- Free expedited shipping.
- No membership fees.
- Doctor-led plans, ongoing doctor support.
Why do people explore mounjaro® therapy?
Lead with type 2 diabetes management — the FDA-approved branded tirzepatide standard.
Glycemic Control
- A1C reduction
- Dual incretin response
- FDA T2D label
Weight Loss
- Secondary benefit
- Off-label use
- Doctor-determined
Cardiometabolic
- Better lipid panel
- Lower BP signals
- Improved insulin
Appetite Control
- Slows digestion
- Reduces cravings
- Dual incretin
Manage type 2 diabetes with FDA-approved tirzepatide.
Mounjaro® is the Eli Lilly pen FDA-approved for glycemic control in adults with type 2 diabetes — same molecule as Zepbound and compounded tirzepatide, with manufacturer savings card support.
Mounjaro is brand-name tirzepatide manufactured by Eli Lilly and shipped as a factory-sealed prefilled pen. Every unit is dose-standardized and produced under FDA-inspected manufacturing. It was FDA-approved on May 13, 2022 for glycemic control — as an adjunct to diet and exercise — in adults with type 2 diabetes. The active molecule is chemically identical to Zepbound® and to compounded tirzepatide; what differs is the FDA-approved indication and the manufacturer support program.
Your doctor may prescribe Mounjaro when you have a type 2 diabetes diagnosis, qualify for insurance or the Mounjaro Savings Card, or prefer a branded pen with Eli Lilly’s patient support. Off-label weight-loss use is doctor-determined based on your individual clinical picture; patients seeking an on-label weight-management option are generally routed to Zepbound. The choice between Mounjaro, Zepbound, and compounded tirzepatide is about indication, coverage, and clinical fit — part of our broader approach to weight loss.
Complete a quick online health intake
STEP
1
Share your health profile online. A US-licensed doctor reviews your fit and decides whether peptide therapy is right for you.
Receive your prescription at your door
STEP
2
If approved, your custom prescription ships free and overnight in temperature-controlled packaging, arriving safely at your home.
Get continuous care from your doctor
STEP
3
Message your care team anytime for dose adjustments, check-ins, and ongoing support that keeps you progressing toward your goals.
Why choose Peptide12?
Patients pick us for clinical rigor, transparent pricing, and care that doesn’t disappear after checkout.
FDA-registered pharmacies
Every prescription is compounded by FDA-registered 503A/503B pharmacies. Batch testing and certificates of analysis available on request.
US-licensed doctors
MDs licensed in your state, not just an order form. Your doctor titrates dosing and answers messages directly.
Transparent pricing
One flat price per protocol. No membership fees, no insurance hassle, no surprise charges. HSA and FSA accepted. Cancel anytime.
Care that doesn’t disappear
Message your doctor through your patient portal whenever you need to. Most replies within hours, never longer than 24.
What patients say
Real outcomes from people on this protocol, all under doctor supervision.
“A1C went from 9.1 to 6.4 in seven months on Mounjaro 7.5 mg. Insurance covered it after the team handled the prior auth. The pen is genuinely simple to use.”
Owen T.
Louisville, KY
“Type 2 since 2018, never could stick with metformin alone. Mounjaro plus the savings card brought me to $25 a month and my fasting glucose is finally in range.”
Adriana P.
Tampa, FL
“My endocrinologist switched me from Ozempic to Mounjaro for the dual incretin effect. A1C dropped another full point and I lost 22 lb without trying.”
Reginald K.
Minneapolis, MN
“Insurance routed me to Mounjaro because of my T2D diagnosis. Three months in, A1C is 6.7, blood pressure is down, and the nausea passed after the first titration step.”
Priya N.
Richmond, VA
“I wanted the branded Lilly pen, not a compounded vial. The care team verified my benefits, set up the savings card, and shipped it the same week. Smooth process.”
Brendan O.
Madison, WI
“Diabetic for nine years, prediabetic A1C now at 5.9 on Mounjaro 10 mg. Lost 31 lb as a bonus. The doctor was clear that weight loss is off-label and a side benefit.”
Yolanda S.
Kansas City, MO
Frequently asked questions
Supporting Studies
- 1.Frías et al. — SURPASS-2: Tirzepatide vs. Semaglutide Once Weekly in T2D (NEJM, 2021)
- 2.Rosenstock et al. — SURPASS-1: Tirzepatide Monotherapy in T2D (Lancet, 2021)
- 3.FDA prescribing information — Mounjaro® (tirzepatide) injection
- 4.FDA — Compounding and the FDA: Questions and Answers
- 5.NIH MedlinePlus — Tirzepatide Injection